Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY

Bamco Inc. NY reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 46.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,000 shares of the biopharmaceutical company’s stock after selling 26,000 shares during the quarter. Bamco Inc. NY’s holdings in Xenon Pharmaceuticals were worth $1,204,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at $32,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $39,000. Osaic Holdings Inc. lifted its stake in Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares in the last quarter. L1 Capital Pty Ltd purchased a new position in Xenon Pharmaceuticals during the 2nd quarter valued at about $41,000. Finally, State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 610 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Wolfe Research began coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Wedbush cut their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $71.88.

Xenon Pharmaceuticals Price Performance

XENE stock opened at $54.66 on Tuesday. The business’s 50-day moving average is $43.97 and its two-hundred day moving average is $42.07. The firm has a market capitalization of $4.55 billion, a P/E ratio of -12.54 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period last year, the business earned ($0.84) earnings per share. On average, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 270,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at $361,980. The trade was a 97.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrea Difabio sold 2,607 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the transaction, the insider owned 4,893 shares of the company’s stock, valued at $294,118.23. This trade represents a 34.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 336,707 shares of company stock worth $19,622,565 over the last 90 days. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.